UK biotech takes on personalised cancer therapy side effects

22 December 2024

Professor Karl Peggs (UCL Cancer Institute), a small shareholder in Autolus, said: “It seems to deliver a therapy that looks to have a better toxicity profile than the drugs that are currently available”.